4th Jul 2019. 9.00am

Regency View:


Regency View:


Codemasters release F1 2019

Codemasters announced the release of F1 2019, the official video game of the 2019 FIA Formula One World Championships.

F1 2019 is the latest instalment in the award-winning franchise that features all of the official cars, teams, drivers and circuits from the current F1 season. It’s available on the PlayStation 4 computer entertainment system, the Xbox One family of devices including the Xbox One X and Windows PC (DVD and via Steam).

CEO Frank Sagnier, commented “F1 2019 has received widespread critical acclaim in the run up to release and we are excited for our community to play the next instalment of this franchise”.

“Within this year’s version we have been able to add several new features including the addition of F2, Senna and Prost challenges as part of the Legend Edition which launched on 25th June with three days early access, Career Mode Driver Transfers, as well as integrating league racing and F1 Esports for fans who wish to race competitively.”

Whilst the shares have retreated from their highs in recent weeks, we remain very bullish on this stock and the release of their flagship F1 game is likely to provide a positive catalyst.

Clinigen gains marketing rights for two jet-lag drugs

Clinigen has been granted marketing authorisations for Melatonin Oral Solution and Melatonin Film-Coated Tablets by the Medicines and Healthcare products Regulatory Agency (MHRA). Both forms are indicated for the short-term treatment of jet-lag in adults.

Obtaining marketing authorisations for a previously unlicensed product is an example of Clinigens unlicensed to licensed (UL2L) strategy.

CEO Shaun Chilton, commented ‘Obtaining MHRA approval for Melatonin has been driven by our dedicated team, which has shown a real determination to address this unmet medical need in the UK. This approval will ensure healthcare professionals can manage adult patients experiencing jet-lag with a licensed product, where before there was none.

“Identifying and developing products to offer licensed options to prescribers and patients is an important part of our strategy in Commercial Medicines. We are continuing to explore and invest to further strengthen and diversify the portfolio.’

The shares are currently consolidating near their highs for the year and we remain nicely up on our position.

D4t4 Solutions in ‘robust shape’ as annual revenue and profits surge

As anticipated, D4t4’s final results (announced on June 25th) made for impressive reading…

Revenue jumped 37% to £25.2m and pre-tax profit almost doubled to £6.3m. D4t4’s own intellectual property product revenue has increased in the year to £9.2m from £6.8m, driven by the increase in sales of both Celebrus customer data platform and hybrid cloud data platform.

The headline numbers have been backed up by another hike in their dividend. For the year, the company is paying a dividend of 3p, up 20% from 2.5p last year.


All content is provided for general information only and should not be construed as any form of advice or personal recommendation. The provision of this content is not regulated by the Financial Conduct Authority.